Symbols

ABVX

Abivax·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 1

Consensus Rating "Buy"

Significant Net Income Decline

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ABVX

Abivax Sa

A biotechnology company focused on harnessing the body's natural regulatory mechanisms to modulate the clinical stages of chronic inflammatory diseases

Industry

Biological Technology

Established Date

12/04/2013

Listing Date

10/20/2023

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.abivax.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

7-11 boulevard Haussmann, 75009 Paris, France

Business

Introduction

Abivax Sa was incorporated on December 4, 2013 under the laws of France. The company is a clinical-stage biotechnology company focused on developing therapies that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is currently evaluating the lead drug candidate, Oberfazmod, in a Phase 3 clinical trial for the treatment of moderate-to-severe active ulcerative colitis in adults.

Company Financials

EPS

Revenue & Expenses

ABVX has released its 2025 Q3 earnings report, with revenue of 2.40M, reflecting a YoY change of 62.47%, and net profit of -179.97M, showing a YoY change of -192.39%. The Sankey diagram below clearly presents ABVX's revenue sources and cost distribution.